Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acolbifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 0.98 |
| ▸ | ESR2 known ✓ | Q92731 | 16/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acolbifene SCHEMBL29351361 | 0.99 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL4447852 | 0.99 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL406183 | 0.99 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL7207561 | 0.99 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL15019602 | 0.98 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL7054458 | 0.95 | ESR1 (0.91) | ESR1ESR2 | |
| Acolbifene SCHEMBL28088521 | 0.93 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL4804921 | 0.92 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL14856500 | 0.90 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.90 | ESR1 (0.91) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2020-02-04 | — | — | US | disclosed |
| EP-2582371-B1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | ENDORECHERCHE INC (CA) | 2019-10-16 | — | — | EP | disclosed |
| US-20170290847-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. | 2017-10-12 | — | — | US | disclosed |
| US-9744177-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2017-08-29 | — | — | US | disclosed |
| EP-3116510-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | Endorecherche, Inc. (CA) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015135061-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. (CA) | 2015-09-17 | — | — | WO | disclosed |
| US-20150250802-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| EP-2582371-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | Endorecherche, Inc. (CA) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011156908-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | ENDORECHERCHE, INC. (CA) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312925-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | ENDORECHERCHE, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250802-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | SHBG, CYP19A1, AR | ESR1 52/4885ESR2 46/4885 |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | SHBG, CYP19A1, AR | ESR1 52/4885ESR2 46/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ESR1 2889/4885ESR2 3881/4885 |
| US-20170290847-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | SHBG, CYP19A1, AR | ESR1 52/4885ESR2 46/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ESR1 2396/4885ESR2 1128/4885 |
| US-20110312925-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | SHBG, ESRRA, ESR2 | ESR1 8/4885ESR2 3/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ESR1 2889/4885ESR2 3881/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ESR1 2396/4885ESR2 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.